Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ)
CNY 23.75
(-0.88%)
CNY 23.75
(-0.88%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.17 Billion CNY | -20.56% |
| 2022 | 1.52 Billion CNY | 23.76% |
| 2021 | 1.23 Billion CNY | 15.38% |
| 2020 | 1.07 Billion CNY | 34.88% |
| 2019 | 793.95 Million CNY | 28.94% |
| 2018 | 615.73 Million CNY | 48.84% |
| 2017 | 413.7 Million CNY | 73.31% |
| 2016 | 238.71 Million CNY | 38.89% |
| 2015 | 171.87 Million CNY | 17.67% |
| 2014 | 146.05 Million CNY | 50.16% |
| 2013 | 97.27 Million CNY | 24.15% |
| 2012 | 78.35 Million CNY | 20.24% |
| 2011 | 65.16 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 268.99 Million CNY | 9.12% |
| 2024 Q2 | 255.9 Million CNY | -22.99% |
| 2024 Q1 | 332.31 Million CNY | -9.45% |
| 2023 FY | 1.21 Billion CNY | -20.56% |
| 2023 Q1 | 297.81 Million CNY | -21.08% |
| 2023 Q4 | 367 Million CNY | 43.52% |
| 2023 Q2 | 294.29 Million CNY | -1.18% |
| 2023 Q3 | 255.71 Million CNY | -13.11% |
| 2022 Q2 | 393.44 Million CNY | -27.5% |
| 2022 Q1 | 542.68 Million CNY | 101.1% |
| 2022 Q4 | 377.33 Million CNY | 74.95% |
| 2022 Q3 | 215.68 Million CNY | -45.18% |
| 2022 FY | 1.52 Billion CNY | 23.76% |
| 2021 Q4 | 269.86 Million CNY | -19.02% |
| 2021 Q1 | 312.51 Million CNY | 47.05% |
| 2021 Q2 | 319.95 Million CNY | 2.38% |
| 2021 FY | 1.23 Billion CNY | 15.38% |
| 2021 Q3 | 333.24 Million CNY | 4.15% |
| 2020 Q3 | 261.26 Million CNY | -23.61% |
| 2020 Q2 | 342 Million CNY | 34.08% |
| 2020 Q1 | 255.07 Million CNY | 7.56% |
| 2020 FY | 1.07 Billion CNY | 34.88% |
| 2020 Q4 | 212.52 Million CNY | -18.65% |
| 2019 Q3 | 191.3 Million CNY | 2.95% |
| 2019 Q2 | 185.82 Million CNY | 3.42% |
| 2019 FY | 793.95 Million CNY | 28.94% |
| 2019 Q4 | 237.14 Million CNY | 23.96% |
| 2019 Q1 | 179.68 Million CNY | -10.44% |
| 2018 Q3 | 145.19 Million CNY | 6.43% |
| 2018 Q2 | 136.41 Million CNY | 2.18% |
| 2018 Q1 | 133.5 Million CNY | -3.77% |
| 2018 FY | 615.73 Million CNY | 48.84% |
| 2018 Q4 | 200.62 Million CNY | 38.18% |
| 2017 Q4 | 138.73 Million CNY | 23.21% |
| 2017 Q1 | 77.71 Million CNY | -5.93% |
| 2017 Q2 | 84.65 Million CNY | 8.93% |
| 2017 FY | 413.7 Million CNY | 73.31% |
| 2017 Q3 | 112.59 Million CNY | 33.0% |
| 2016 FY | 238.71 Million CNY | 38.89% |
| 2016 Q4 | 82.61 Million CNY | 36.51% |
| 2016 Q3 | 60.52 Million CNY | 16.87% |
| 2016 Q2 | 51.78 Million CNY | 18.72% |
| 2016 Q1 | 43.61 Million CNY | -32.2% |
| 2015 FY | 171.87 Million CNY | 17.67% |
| 2015 Q4 | 64.32 Million CNY | 49.34% |
| 2015 Q3 | 43.07 Million CNY | 16.66% |
| 2015 Q2 | 36.92 Million CNY | 35.43% |
| 2015 Q1 | 27.26 Million CNY | -44.06% |
| 2014 Q1 | 54.04 Million CNY | 0.0% |
| 2014 Q4 | 48.74 Million CNY | 38.34% |
| 2014 Q3 | 35.23 Million CNY | 3686.06% |
| 2014 Q2 | 930.59 Thousand CNY | -98.28% |
| 2014 FY | 146.05 Million CNY | 50.16% |
| 2013 FY | 97.27 Million CNY | 24.15% |
| 2012 FY | 78.35 Million CNY | 20.24% |
| 2011 FY | 65.16 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 3.35 Billion CNY | 64.943% |
| Hangzhou Tigermed Consulting Co., Ltd. | 358.41 Million CNY | -227.939% |
| Dirui Industrial Co.,Ltd. | 387.16 Million CNY | -203.589% |
| Beijing Strong Biotechnologies, Inc. | 702.74 Million CNY | -67.257% |
| Medicalsystem Biotechnology Co., Ltd. | 562.06 Million CNY | -109.12% |
| Maccura Biotechnology Co.Ltd | 1.18 Billion CNY | 0.426% |
| Guangdong Hybribio Biotech Co.,Ltd. | 631.43 Million CNY | -86.145% |
| BGI Genomics Co., Ltd. | 1.93 Billion CNY | 39.39% |
| Amoy Diagnostics Co., Ltd. | 574.96 Million CNY | -104.427% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 479.96 Million CNY | -144.888% |